Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 37Prostatic Neoplasms 12Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 3Fibrosis 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Intraductal, Noninfiltrating 3Uterine Cervical Neoplasms 2Thyroid Nodule 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pleural Effusion, Malignant 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma 2Lymphedema 2Leukemia, Myeloid, Acute 2Leukemia 2Inflammatory Breast Neoplasms 2Infertility 2Hodgkin Disease 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Anatomic Stage III Breast Cancer AJCC v8 2

Interventions

3-Iodobenzylguanidine 14Temozolomide 6lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4anlotinib 4Specimen Handling 4Everolimus 4Radiotherapy 3Phenoxybenzamine 3Magnetic Resonance Spectroscopy 3Doxorubicin 36-fluorodopamine 33-fluorobenzylguanidine 3pegfilgrastim 2olaparib 2fluorodopa F 18 2cabozantinib 2belzutifan 2Nivolumab 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Filgrastim 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Biopsy 2Axitinib 2Adrenalectomy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × High-Energy Shock Waves × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡